Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

March 31, 2024

Conditions

Colorectal CancerPancreatic Adenocarcinoma

Interventions

DRUG

Trametinib

Taken orally once daily

DRUG

Ruxolitinib

Taken orally twice daily

Trial Locations (1)

RECRUITING

National Cancer Centre, Singapore

All Listed Sponsors

lead

National Cancer Centre, Singapore

OTHER